IVA vs. WVE, NRIX, ETNB, NUVB, PLRX, PAHC, STOK, TNGX, GHRS, and COGT
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Wave Life Sciences (WVE), Nurix Therapeutics (NRIX), 89bio (ETNB), Nuvation Bio (NUVB), Pliant Therapeutics (PLRX), Phibro Animal Health (PAHC), Stoke Therapeutics (STOK), Tango Therapeutics (TNGX), GH Research (GHRS), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical preparations" industry.
Inventiva (NASDAQ:IVA) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.
Inventiva currently has a consensus price target of $17.00, indicating a potential upside of 363.22%. Wave Life Sciences has a consensus price target of $11.17, indicating a potential upside of 80.69%. Given Inventiva's stronger consensus rating and higher probable upside, equities analysts plainly believe Inventiva is more favorable than Wave Life Sciences.
In the previous week, Inventiva and Inventiva both had 3 articles in the media. Inventiva's average media sentiment score of 0.94 beat Wave Life Sciences' score of 0.92 indicating that Inventiva is being referred to more favorably in the media.
Wave Life Sciences has higher revenue and earnings than Inventiva.
Inventiva has a net margin of 0.00% compared to Wave Life Sciences' net margin of -54.61%.
19.1% of Inventiva shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 31.1% of Wave Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Inventiva has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.99, meaning that its share price is 199% less volatile than the S&P 500.
Wave Life Sciences received 330 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 67.18% of users gave Wave Life Sciences an outperform vote.
Summary
Inventiva beats Wave Life Sciences on 10 of the 14 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
